Update – CDC recommendations for managing and reporting Shigella infections with possible reduced susceptibility to ciprofloxacin
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Update – CDC recommendations for managing and reporting Shigella infections with possible reduced susceptibility to ciprofloxacin

Filetype[PDF-645.41 KB]


  • English
    • Details Related Documents You May Also Like

    Details:

    • Journal Article:
      HAN
    • Corporate Authors:
      Centers for Disease Control and Prevention (U.S.)
    • Description:
      Distributed via the CDC Health Alert Network

      May 25, 2018, 1100 ET (11:00 AM ET)

      CDC HAN-00411

      This Health Alert Network (HAN) Update provides current recommendations on management and reporting of Shigella infections that have been treated with ciprofloxacin or azithromycin and resulted in possible clinical treatment failure. This is a follow-up to HAN 401: CDC Recommendations for Diagnosing and Managing Shigella Strains with Possible Reduced Susceptibility to Ciprofloxacin.

      The Centers for Disease Control and Prevention (CDC) continues to identify an increasing number of Shigella isolates that test within the susceptible range for the fluoroquinolone antibiotic ciprofloxacin (minimum inhibitory concentration [MIC] values of 0.12-1 μg/mL), but harbor one or more resistance mechanisms. CDC remains concerned about potential clinical failures with fluoroquinolone treatment.

      Clinicians should carefully monitor patients with Shigella infections who require fluoroquinolone treatment and report any possible treatment failures. If treatment failure is suspected, clinicians should submit a stool specimen for antimicrobial susceptibility testing, and consider consulting an infectious disease specialist to identify best treatment options.

      CDC has also identified an increasing number of Shigella isolates with azithromycin MICs that exceed the epidemiological cutoff value (ECV), and is requesting reports of any possible treatment failures occurring among patients with Shigella infections treated with azithromycin (see below).

      Shigellosis is a nationally notifiable condition; all cases should be reported to local health departments.

    • Subjects:
    • Series:
      HAN ; 411
    • Document Type:
      HAN Health Update
    • Place as Subject:
      United States
    • Location:
      North America
    • Collection(s):
    • Main Document Checksum:
    • Download URL:
    • File Type:

    Supporting Files

    • No Additional Files

    More +

    Related Documents

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov